Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 26 | 2020 | 272 | 2.970 |
Why?
|
| Status Epilepticus | 13 | 2021 | 74 | 2.500 |
Why?
|
| Stroke | 28 | 2023 | 2163 | 1.950 |
Why?
|
| Clinical Trials as Topic | 14 | 2020 | 848 | 1.620 |
Why?
|
| Phenytoin | 9 | 2021 | 27 | 1.400 |
Why?
|
| Ischemic Attack, Transient | 9 | 2021 | 167 | 1.350 |
Why?
|
| Anticonvulsants | 10 | 2021 | 223 | 1.330 |
Why?
|
| Research Design | 14 | 2021 | 729 | 1.230 |
Why?
|
| Glyburide | 8 | 2018 | 19 | 1.080 |
Why?
|
| Brain Edema | 9 | 2018 | 50 | 1.070 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2021 | 373 | 1.030 |
Why?
|
| Antiparkinson Agents | 8 | 2020 | 34 | 0.960 |
Why?
|
| Aspirin | 7 | 2020 | 295 | 0.880 |
Why?
|
| Hypoglycemic Agents | 8 | 2018 | 362 | 0.830 |
Why?
|
| Double-Blind Method | 24 | 2023 | 1738 | 0.760 |
Why?
|
| Valproic Acid | 9 | 2021 | 93 | 0.740 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2019 | 28 | 0.680 |
Why?
|
| Severity of Illness Index | 12 | 2019 | 1851 | 0.670 |
Why?
|
| Steroids | 1 | 2019 | 84 | 0.650 |
Why?
|
| Creatine | 5 | 2016 | 30 | 0.640 |
Why?
|
| Transcranial Direct Current Stimulation | 4 | 2023 | 111 | 0.630 |
Why?
|
| Aphasia | 4 | 2023 | 119 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2021 | 931 | 0.620 |
Why?
|
| Brain Ischemia | 8 | 2020 | 665 | 0.550 |
Why?
|
| Humans | 80 | 2023 | 68618 | 0.540 |
Why?
|
| Aged | 41 | 2023 | 14862 | 0.520 |
Why?
|
| Dopamine Agents | 3 | 2017 | 56 | 0.520 |
Why?
|
| Benzodiazepines | 6 | 2021 | 130 | 0.510 |
Why?
|
| Middle Aged | 46 | 2021 | 21147 | 0.500 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2021 | 84 | 0.500 |
Why?
|
| Disease Progression | 9 | 2017 | 1038 | 0.480 |
Why?
|
| Treatment Outcome | 24 | 2021 | 7029 | 0.470 |
Why?
|
| Male | 49 | 2023 | 37321 | 0.420 |
Why?
|
| Female | 49 | 2023 | 38074 | 0.410 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 438 | 0.380 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 649 | 0.380 |
Why?
|
| Deglutition Disorders | 3 | 2019 | 297 | 0.370 |
Why?
|
| Patient Compliance | 2 | 2018 | 402 | 0.370 |
Why?
|
| Neuroprotective Agents | 3 | 2018 | 317 | 0.360 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 247 | 0.350 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 4 | 2020 | 20 | 0.350 |
Why?
|
| Intracranial Hemorrhages | 3 | 2020 | 80 | 0.330 |
Why?
|
| Cerebral Hemorrhage | 3 | 2021 | 198 | 0.320 |
Why?
|
| Stroke Rehabilitation | 3 | 2023 | 335 | 0.310 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2020 | 124 | 0.310 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 249 | 0.290 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2017 | 30 | 0.280 |
Why?
|
| Random Allocation | 3 | 2019 | 442 | 0.280 |
Why?
|
| Bayes Theorem | 3 | 2019 | 307 | 0.270 |
Why?
|
| Endpoint Determination | 3 | 2021 | 82 | 0.260 |
Why?
|
| Adult | 26 | 2021 | 21403 | 0.260 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2019 | 239 | 0.260 |
Why?
|
| Secondary Prevention | 4 | 2021 | 291 | 0.260 |
Why?
|
| Accidental Falls | 3 | 2017 | 84 | 0.260 |
Why?
|
| Anticoagulants | 2 | 2018 | 356 | 0.250 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1054 | 0.250 |
Why?
|
| Child | 10 | 2021 | 6405 | 0.250 |
Why?
|
| Computer Simulation | 3 | 2021 | 706 | 0.250 |
Why?
|
| Brain Infarction | 2 | 2016 | 54 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 4 | 2020 | 186 | 0.240 |
Why?
|
| Disability Evaluation | 3 | 2020 | 298 | 0.240 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 4848 | 0.230 |
Why?
|
| Young Adult | 13 | 2021 | 5717 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2007 | 621 | 0.220 |
Why?
|
| Research Subjects | 2 | 2016 | 45 | 0.220 |
Why?
|
| Speech-Language Pathology | 2 | 2020 | 24 | 0.220 |
Why?
|
| Hemorrhage | 3 | 2019 | 328 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2019 | 448 | 0.210 |
Why?
|
| Recovery of Function | 3 | 2021 | 506 | 0.210 |
Why?
|
| Sample Size | 4 | 2012 | 79 | 0.210 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2021 | 2 | 0.200 |
Why?
|
| Time Factors | 6 | 2021 | 4655 | 0.200 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 17 | 0.190 |
Why?
|
| Levodopa | 1 | 2020 | 12 | 0.190 |
Why?
|
| Ischemia | 2 | 2019 | 229 | 0.190 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2021 | 44 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 329 | 0.180 |
Why?
|
| Fibrinolytic Agents | 4 | 2020 | 377 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2016 | 342 | 0.180 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Adolescent | 11 | 2021 | 8912 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2021 | 107 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2021 | 2358 | 0.180 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 99 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1465 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2018 | 118 | 0.180 |
Why?
|
| Cerebral Infarction | 2 | 2020 | 103 | 0.180 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 2077 | 0.180 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 142 | 0.170 |
Why?
|
| Genotype | 2 | 2020 | 786 | 0.170 |
Why?
|
| Child, Preschool | 7 | 2021 | 3187 | 0.170 |
Why?
|
| Genetic Variation | 1 | 2020 | 220 | 0.170 |
Why?
|
| Rare Diseases | 1 | 2019 | 41 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2020 | 296 | 0.170 |
Why?
|
| Huntington Disease | 1 | 2018 | 15 | 0.160 |
Why?
|
| Speech Therapy | 1 | 2018 | 19 | 0.160 |
Why?
|
| Emergency Service, Hospital | 3 | 2020 | 711 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 36 | 0.160 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 25 | 0.160 |
Why?
|
| Eating | 1 | 2019 | 119 | 0.160 |
Why?
|
| Dominance, Cerebral | 1 | 2018 | 65 | 0.150 |
Why?
|
| Smartphone | 1 | 2018 | 69 | 0.150 |
Why?
|
| Body Weight | 1 | 2020 | 554 | 0.150 |
Why?
|
| United States | 9 | 2020 | 7367 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 792 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 148 | 0.150 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 157 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 185 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2014 | 58 | 0.140 |
Why?
|
| Dementia | 1 | 2019 | 158 | 0.140 |
Why?
|
| Models, Biological | 1 | 2021 | 981 | 0.140 |
Why?
|
| Mobile Applications | 1 | 2018 | 138 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1745 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Telecommunications | 1 | 2016 | 31 | 0.140 |
Why?
|
| Deglutition | 1 | 2019 | 221 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 310 | 0.140 |
Why?
|
| Indans | 1 | 2016 | 20 | 0.140 |
Why?
|
| Canada | 2 | 2016 | 267 | 0.130 |
Why?
|
| Risk Factors | 7 | 2021 | 5731 | 0.130 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 306 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2016 | 113 | 0.130 |
Why?
|
| Deoxyguanosine | 1 | 2015 | 4 | 0.130 |
Why?
|
| Sensation Disorders | 1 | 2015 | 14 | 0.120 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 319 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 77 | 0.120 |
Why?
|
| Linear Models | 2 | 2016 | 521 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 106 | 0.120 |
Why?
|
| Early Diagnosis | 2 | 2020 | 122 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 2223 | 0.110 |
Why?
|
| Communication | 1 | 2016 | 329 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 565 | 0.110 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2015 | 86 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 1515 | 0.110 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 517 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 160 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2015 | 330 | 0.110 |
Why?
|
| Informed Consent | 2 | 2016 | 127 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 176 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.100 |
Why?
|
| Cerebrum | 1 | 2012 | 20 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 3259 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 2012 | 36 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.100 |
Why?
|
| Postural Balance | 1 | 2012 | 93 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2015 | 753 | 0.090 |
Why?
|
| Melanoma | 1 | 2013 | 335 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2020 | 249 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 334 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 375 | 0.080 |
Why?
|
| Cognition | 2 | 2010 | 513 | 0.080 |
Why?
|
| Comprehension | 1 | 2009 | 71 | 0.080 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2010 | 138 | 0.080 |
Why?
|
| Logistic Models | 3 | 2018 | 1420 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.080 |
Why?
|
| Comorbidity | 2 | 2013 | 1426 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 563 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 89 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2019 | 2007 | 0.070 |
Why?
|
| Biomarkers | 3 | 2019 | 1593 | 0.070 |
Why?
|
| Incidence | 3 | 2017 | 1603 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 2800 | 0.070 |
Why?
|
| Algorithms | 1 | 2012 | 1196 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 216 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2014 | 1342 | 0.070 |
Why?
|
| Age Factors | 2 | 2021 | 1864 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2279 | 0.060 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 233 | 0.060 |
Why?
|
| Brain | 2 | 2018 | 2176 | 0.060 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 55 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2018 | 125 | 0.060 |
Why?
|
| Motor Activity | 1 | 2007 | 621 | 0.060 |
Why?
|
| Piracetam | 2 | 2013 | 10 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 807 | 0.060 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2013 | 11 | 0.050 |
Why?
|
| Prognosis | 3 | 2015 | 2093 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1619 | 0.050 |
Why?
|
| Depression | 1 | 2009 | 943 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1553 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2016 | 3705 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2013 | 109 | 0.050 |
Why?
|
| Factor VIIa | 1 | 2021 | 25 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2021 | 8 | 0.050 |
Why?
|
| Hematoma | 1 | 2021 | 47 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 843 | 0.050 |
Why?
|
| Diazepam | 1 | 2021 | 23 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 78 | 0.050 |
Why?
|
| Lorazepam | 1 | 2021 | 54 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2021 | 52 | 0.050 |
Why?
|
| Midazolam | 1 | 2021 | 46 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 238 | 0.050 |
Why?
|
| Pathologists | 1 | 2020 | 10 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 44 | 0.040 |
Why?
|
| Self Administration | 1 | 2021 | 419 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 742 | 0.040 |
Why?
|
| Hematuria | 1 | 2019 | 24 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 51 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 386 | 0.040 |
Why?
|
| Hypotension | 1 | 2019 | 74 | 0.040 |
Why?
|
| Age Distribution | 1 | 2020 | 320 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Speech | 1 | 2020 | 118 | 0.040 |
Why?
|
| Aphasia, Broca | 1 | 2018 | 11 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 223 | 0.040 |
Why?
|
| Medication Adherence | 2 | 2015 | 335 | 0.040 |
Why?
|
| Language Therapy | 1 | 2018 | 9 | 0.040 |
Why?
|
| Education, Medical | 1 | 2020 | 147 | 0.040 |
Why?
|
| Seizures | 1 | 2020 | 279 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 172 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 195 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2020 | 418 | 0.040 |
Why?
|
| Larynx | 1 | 2018 | 49 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 1027 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2018 | 229 | 0.040 |
Why?
|
| Pharynx | 1 | 2018 | 89 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 658 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 948 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 53 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 213 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 294 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 411 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 627 | 0.030 |
Why?
|
| Patient Participation | 1 | 2016 | 146 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 51 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 188 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 216 | 0.030 |
Why?
|
| Selegiline | 1 | 2013 | 3 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 38 | 0.030 |
Why?
|
| Fear | 1 | 2015 | 239 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 215 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 295 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2013 | 72 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2013 | 284 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 770 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2012 | 107 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.030 |
Why?
|
| Patient Safety | 1 | 2013 | 202 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 93 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 392 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 718 | 0.020 |
Why?
|
| Atrophy | 1 | 2010 | 112 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 631 | 0.020 |
Why?
|
| Thalamus | 1 | 2010 | 82 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2009 | 14 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 242 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 107 | 0.020 |
Why?
|
| Vitamins | 1 | 2009 | 134 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 415 | 0.020 |
Why?
|
| Hippocampus | 1 | 2010 | 471 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 689 | 0.020 |
Why?
|
| Medical Futility | 1 | 2006 | 31 | 0.020 |
Why?
|